RAS: Target for Cancer Therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The RAS protein controls signaling pathway are major player in cell growth, its regulation and malignant transformation. Any activation in RAS brings alteration in upstream or downstream signaling component. Activating mutation in RAS is found in approximately 30% of human cancer. RAS plays essential role in tumor maintenance and is therefore an appropriate target for anticancer therapy. Among the anti-RAS strategies that are under evaluation in the clinic are pharmacologic inhibitors designed to prevent: (1) association with the plasma membrane (prenylation and post prenylation inhibitors). (2) Downstream signaling (kinase inhibitor), (3) upstream pathway (kinase inhibitor and monoclonal antibody), (4) Expression of RAS or other component of pathway (siRNA and antisense oligonucleotide). Several of these new therapeutic agents are showing promising result in the clinic and many more are on the way. Here, we review the current status and new hopes for targeting RAS as an anticancer drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Generic name of this antibody is cetuximab, a chimeric IgG1 monoclonal antibody approved for EGFR-detectable metastatic colorectal cancer (57) and squamous cell cancer of the head and neck (58).”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“ERK, which is downstream of RAS, also promotes upregulated expression of EGFR ligand that is transforming growth factor alpha (TGFα), which promotes an autocrine growth loop critical for tumor development (27).”
BackgroundRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 2×
“Moreover, several other human cancer harbors alteration in factors that lie upstream of RAS, leading to over expression or mutational activation of growth factor receptor tyrosine kinase, such as epidermal growth factor (EGFR and ERBB2), or downstream of RAS, such as mutation of B-Raf in melanomas (5, 28).”
BackgroundPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · cited 2×
“So constant activation of RAS will cause extensive actin polymerization membrane ruffling and increased number of focal adhesion (17, 22).”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×
“RAS is mutationally activated in 30% of all cancers, with pancreas (90%), colon (50%), thyroid (50%), lung (30%) and melanoma (25%) having the highest prevalence (4).”
BackgroundThe Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1×
“Therefore, inhibition of post translational modification of RAS can not stop RAS mediated signaling (49).”
BackgroundPost-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Cited by
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Xing, M. (2010) · Thyroid · doi:10.1089/thy.2010.1646 · Cited by 305
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189
“K-Ras have thus far been unsuccessful (13).”
Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Metadata
- Authors
- Saxena, N., Lahiri, S. S., Hambarde, S., & Tripathi, R. P.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 26
- Issue
- 9
- Pages
- 948-955
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2096238248
- Cited by
- 92
- References
- 9
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAS: Target for Cancer Therapy. https://app.cochat.ai/papers/10.1080/07357900802087275
- The paper
- Saxena, N., Lahiri, S. S., Hambarde, S., & Tripathi, R. P. (2008). RAS: Target for Cancer Therapy. Cancer Investigation. https://doi.org/10.1080/07357900802087275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.